Arginine

Arginine

SCHEMBL1287134

N=C(N)NCCC[C@H](N)C(=O)O.O=C(O)c1ccccc1

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACE

The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
OTC P00480 1/20 0.43
POLB P06746 1/20 0.42
KMT2A Q03164 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
DDAH1 O94760 1/20 0.41
CASR P41180 1/20 0.41
KIF11 P52732 4/20 0.40
GRM4 Q14833 2/20 0.39
GRM6 O15303 1/20 0.39
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
DAO P14920 1/20 0.39
TSHR P16473 1/20 0.39
NAPRT Q6XQN6 1/20 0.39
LTA4H P09960 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Arginine SCHEMBL12006798 1.00 OTC (0.43) OTCPOLBKMT2ATDP1DDAH1
Arginine SCHEMBL28911625 0.99 OTC (0.43) OTCPOLBKMT2ATDP1DDAH1
Arginine SCHEMBL4606882 0.92 F10 (0.44) OTCPOLBKMT2ATDP1DDAH1
Arginine SCHEMBL4606883 0.92 F10 (0.44) OTCPOLBKMT2ATDP1DDAH1
L-Citrulline SCHEMBL31412709 0.89 C3AR1 (0.46) OTCPOLBKMT2ATDP1DDAH1
Arginine SCHEMBL28268971 0.88 OTC (0.53) OTCKMT2ADDAH1NOS3NOS1
Arginine SCHEMBL31315051 0.88 CA2 (0.44) OTCPOLBKMT2ATDP1DDAH1
Arginine SCHEMBL28911606 0.88 OTC (0.41) OTCPOLBKMT2ATDP1DDAH1
Arginine SCHEMBL28911624 0.88 OTC (0.41) OTCPOLBKMT2ATDP1DDAH1
Arginine SCHEMBL26914670 0.87 KIF11 (0.46) OTCPOLBKMT2ATDP1DDAH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2624689-A2 ANTIMICROBIAL PACKAGING MATERIAL AND METHODS OF MAKING AND USING THE SAME Cryovac, Inc. (US) 2013-08-14 EP claimed
WO-2012047947-A2 ANTIMICROBIAL PACKAGING MATERIAL AND METHODS OF MAKING AND USING THE SAME CRYOVAC, INC. (US) 2012-04-12 WO claimed
US-12409121-B2 Formulations and methods for preparing stable cosmetic compositions Spinart, LLC (US) 2025-09-09 US disclosed
EP-3802122-A1 METHOD OF MAKING AN ANTIMICROBIAL MULTILAYER FILM Cryovac, LLC (US) 2021-04-14 EP disclosed
US-20200352840-A1 FORMULATIONS AND METHODS FOR PREPARING STABLE COSMETIC COMPOSITIONS Spinart, LLC 2020-11-12 US disclosed
EP-3302707-A1 URINE METABOLITE PROFILES IDENTIFY KIDNEY ALLOGRAFT STATUS Cornell University (US) 2018-04-11 EP disclosed
WO-2016196329-A1 URINE METABOLITE PROFILES IDENTIFY KIDNEY ALLOGRAFT STATUS CORNELL UNIVERSITY (US) 2016-12-08 WO disclosed
US-20130109636-A1 TRI-AMINO RELEASING FULVATE SCHUTT STEVEN R (US) 2013-05-02 US disclosed
WO-2012118532-A1 A TRI AMINO RELEASING FULVATE SCHUTT STEVEN R (US) 2012-09-07 WO disclosed
US-20120220752-A1 TRI-AMINO RELEASING FULVATE SCHUTT STEVEN R (US) 2012-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220752-A1 TRI-AMINO RELEASING FULVATE DAO, PAM, SLC1A5 OTC 1117/4885POLB 890/4885KMT2A 2725/4885
US-20130109636-A1 TRI-AMINO RELEASING FULVATE DAO, AADAT, FGB OTC 3131/4885POLB 2545/4885KMT2A 2152/4885
US-12409121-B2 Formulations and methods for preparing stable cosmetic compositions CUTA, ARG1, ODC1 OTC 4/4885POLB 1583/4885KMT2A 2576/4885
US-20200352840-A1 FORMULATIONS AND METHODS FOR PREPARING STABLE COSMETIC COMPOSITIONS CUTA, ARG1, ODC1 OTC 4/4885POLB 1583/4885KMT2A 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.